Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Return on Sales (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Return on Sales for 16 consecutive years, with 0.05% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 58.0% to 0.05% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.01% through Dec 2025, up 39.0% year-over-year, with the annual reading at 0.01% for FY2025, 39.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.05% at Anika Therapeutics, down from 0.03% in the prior quarter.
  • The five-year high for Return on Sales was 0.17% in Q2 2021, with the low at 5.06% in Q4 2023.
  • Average Return on Sales over 5 years is 0.57%, with a median of 0.08% recorded in 2022.
  • The sharpest move saw Return on Sales plummeted -415bps in 2022, then soared 443bps in 2024.
  • Over 5 years, Return on Sales stood at 0.09% in 2021, then crashed by -4553bps to 4.24% in 2022, then dropped by -19bps to 5.06% in 2023, then soared by 87bps to 0.63% in 2024, then skyrocketed by 92bps to 0.05% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.05%, 0.03%, and 0.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.